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This is a reply letter to Letter to the ‘Editor Hemicrania continua: towards a new classification?’ Fabio Antonaci and
Ottar Sjaastad The Journal of Headache and Pain Citation: 2014, 15:8.To the Editor
The third edition of the International Classification of
Headache Disorders- ICHD-III has recently been pub-
lished in beta [1], or test, format, to focus developments
in headache nosology. The beta version is to “test” and
for the “correction of mistakes”, so your writers’ concerns
[2] need to viewed in that context.
The authors commence with their underlying rationale:
“Naturally, later reported cases, carrying this appellation,
should conform with the original description of this
clinical constellation of symptoms and signs”, referring
to the cases of Sjaastad and Spierings [3]. Now the
ICHD-III beta committee could pause there and say the
new definition conforms by the definition of “to make
like” (Oxford English Dictionary), since like gives some
flexibility, although that may be seen a rather insouciant,
if not specious, approach. The extent to which the pro-
posed definition renders cases like the original is at issue.
Since I have not seen the original cases, and I doubt the
writers have seen any of those I have seen, perhaps this
will not be easily resolved.
Are the movement criteria- 3.4 C2 wrong and lead to
mis-diagnosis? This writers’ view is that 3.4 C2 should
not be sufficient in the absence of any cranial auto-
nomic symptoms. We have seen and documented cases
with strictly lateralized continuous headache, a placebo-
controlled response and then oral response to indometh-
acin, who did not have cranial autonomic symptoms, but
fulfilled C2 [4]. The writers mention cluster headache in
this context as if patients fulfilling the new criteria could
have that condition. However, patients falling into the newCorrespondence: peter.goadsby@kcl.ac.uk
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in any medium, provided the original work is pclassification would be treated correctly, as our index
cases were, and not with oxygen, sumatriptan, verapamil
or lithium, by a mis-diagnosis the writers have opined on
recently; a text that makes good reading [5].
How important is the indomethacin effect? The new
criteria insist on an indomethacin effect. It has always
been troublesome, however, until we understand the
biology, it seems clinically and nosologically sensible; it
is clearly stated in the new criteria. The acronym NIRCH
cannot apply to the cases classified with the new criterion,
“Non” is not an option. The writers state the indomethacin
dose can vary; that is certainly this correspondent’s experi-
ence, and is covered explicitly by the statement- Smaller
maintenance doses are often employed (3.4 Note 1). To say
100–200 mg of indomethacin tests the general analgesic
properties is inconsistent with the fact that many patients
do not respond at all [6]; the inclusion of placebo in the test
we have developed gives these data a strength absent in
previous studies.
Migrainous features and side-locking: what is the issue?
The writers mention migrainous features and vascular
components, neither are mentioned in the new criteria;
the latter is unreferenced, thus hard to understand in
this context. Regarding side-locking, again we have doc-
umented cases otherwise typical with a clear placebo-
controlled indomethacin effect [4] that are not side
locked. Indeed, this correspondent has also seen strictly
lateralized headache that swaps sides and is not indo-
methacin responsive: which is the greater feature with
which to classify such cases?
Are cranial autonomic features part of hemicrania
continua? The writers describe the inclusion of certain
cranial autonomic features as a “blunder”, specifically
they write: “Forehead/facial sweating is not part of the
HC-picture.” I would invite them to consider the originalpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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sensitive to light. It would also tear, and there would be
profuse right-sided forehead perspiration.” One would
predict the cranial autonomic activation to vary and there
is a good physiological basis for this [7].
How should we define the length of a remission? The
writers feel the Committee has been too lenient with a
remission of one day. I would not quibble; one would invite
studies of the length of remission of cases with clear-cut
indomethacin effects to see what is a reasonable interval.
Reductionist logic tells you any length spontaneous remis-
sion deserves our attention in order to learn from it.
I would submit the diagnosis has not changed, rather
our understanding is evolving. A rather wise and astute
clinician once wrote: “One can, however, hardly expect
all the facets of this headache to be established by now.
Only experience will clarify the entire panorama of
symptoms and signs in this headache; only then will its
nosologic position be ascertained” [8]. The ICHD Section
III sub-committee would entirely agree and continues to
attempt this process of clarification so ably commenced
by your senior writer.
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